Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.

ABSTRACT: Major depressive disorder (MDD) is a chronic condition that affects one in six adults in the US during their lifetime. The current practice of antidepressant medication prescription is a trial-and-error process. Additionally, over a third of patients with MDD fail to respond to two or more antidepressant treatments. There are no valid clinical markers to personalize currently available antidepressant medications, all of which have similar mechanisms targeting monoamine neurotransmission. The goal of this review is to summarize the recent findings of immune dysfunction in patients with MDD, the utility of inflammatory markers to personalize treatment selection, and the potential of targeting inflammation to develop novel antidepressant treatments. To personalize antidepressant prescription,

SUBMITTER: Jha MK 

PROVIDER: S-EPMC5796181 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature